Global pharmaceutical leader Lupin Limited has announced the launch of Rivaroxaban Tablets USP, 2.5 mg in the U.S. market. This follows the final approval of its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA).
Rivaroxaban Tablets USP, 2.5 mg is the generic equivalent of Xarelto® (Janssen Pharmaceuticals, Inc.) and is indicated for:
- Reducing major cardiovascular risks in patients with coronary artery disease (CAD).
- Lowering thrombotic vascular event risks in patients with peripheral artery disease (PAD), including those who have undergone recent lower extremity revascularization.
With an estimated annual sales of USD 446 million (IQVIA MAT January 2025), Rivaroxaban remains a widely prescribed anticoagulant in the U.S. market. Lupin’s entry strengthens the availability of this cost-effective alternative, benefiting patients and healthcare providers alike.
In the meantime, Lupin’s shares closed today at ₹2,029.00 after opening at ₹2,020.00. The stock reached a high of ₹2,047.65 and a low of ₹2,004.00 during the session. Currently, Lupin trades below its 52-week high of ₹2,402.90 but remains well above its 52-week low of ₹1,493.30.
